| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Microbiology and Immunology [N. B., B. B.], and Surgery [A. B.], University of California at Los Angeles School of Medicine and Jonsson Comprehensive Cancer Center, Center for Health Sciences, Los Angeles, California 90095-1747
Hormonal treatment of advanced prostatic cancer patients generally results in an initially beneficial response, but the treated patients develop hormonally resistant disease in which no curative therapy is currently available. Recent studies have revealed that interleukin 6 (IL-6) is a growth factor for myeloma, renal cell carcinoma, and certain T-cell lymphomas. Further, IL-6 has been shown to block apoptosis induced by p53, transforming growth factor ß, and certain cancer chemotherapeutic compounds. The objective of the present study was to determine whether IL-6 is a growth factor for two human prostate cancer lines and whether it protects the tumor cells from drug-induced cell death. Two hormone-independent prostate cell lines were used in this study, namely PC-3 and DU145, and these have been shown to be relatively resistant to cis-diamminedichloroplatinum (CDDP), etoposide (VP-16), and adriamycin (ADR). Both cell lines express IL-6 mRNA and secrete IL-6 constitutively. The addition of anti-IL-6 antiserum to the cell lines resulted in a significant inhibition of cell growth up to day 2, and when additional antibody was added at day 2 the inhibition persisted for 4 days. The coaddition of anti-IL-6 antiserum and CDDP or VP-16 resulted in synergy in cytotoxicity in both cell lines, whereas the combination of antibody and ADR or suramin resulted only in additive effects. Sequential treatment revealed that anti-IL-6 antibody was required to achieve synergy, whereas either sequence of pretreatment resulted in synergy with anti-IL-6 and CDDP but not with VP-16. CDDP treatment of tumor cells down-regulated IL-6 mRNA expression and IL-6 secretion. The present findings demonstrate that IL-6 is an autocrine/paracrine growth factor for DU145 and PC-3 prostate lines. Additionally, the secretion of this cytokine protects the tumor cells against the cytotoxic effect of CDDP and VP-16 and its neutralization sensitizes the cells to cytotoxicity. Overall, the studies suggest that agents that can down-regulate or inhibit protective factors in tumors may overcome drug resistance.
1 This work was supported in part by the Boiron Research Foundation, the Concern Foundation and by the Associazione Italiana per la Ricerca sul Cancro.
2 To whom requests for reprints should be addressed, at Department of Microbiology and Immunology, University of California at Los Angeles School of Medicine, 10833 Le Conte Avenue, Los Angeles, CA 90024-1747.
Received 5/18/95. Accepted 8/16/95.
This article has been cited by other articles:
|
|
 |
|
  M. Komatsu, K. Hiyama, K. Tanimoto, M. Yunokawa, K. Otani, M. Ohtaki, E. Hiyama, J. Kigawa, M. Ohwada, M. Suzuki, et al. Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers. Mol. Cancer Ther., March 1, 2006; 5(3): 767 - 775. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Yuan, F. J. Liddle, S. Mahajan, and D. A. Frank IL-6-induced survival of colorectal carcinoma cells is inhibited by butyrate through down-regulation of the IL-6 receptor Carcinogenesis, November 1, 2004; 25(11): 2247 - 2255. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. N. Papandreou, D. D. Daliani, D. Nix, H. Yang, T. Madden, X. Wang, C. S. Pien, R. E. Millikan, S.-M. Tu, L. Pagliaro, et al. Phase I Trial of the Proteasome Inhibitor Bortezomib in Patients With Advanced Solid Tumors With Observations in Androgen-Independent Prostate Cancer J. Clin. Oncol., June 1, 2004; 22(11): 2108 - 2121. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Amantana, C. A. London, P. L. Iversen, and G. R. Devi X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells Mol. Cancer Ther., June 1, 2004; 3(6): 699 - 707. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. E. Barton, J. G. Karras, T. F. Murphy, A. Barton, and H. F-S. Huang Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: Direct STAT3 inhibition induces apoptosis in prostate cancer lines Mol. Cancer Ther., January 1, 2004; 3(1): 11 - 20. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. A. Oskeritzian, W. Zhao, A. L. Pozez, N. M. Cohen, M. Grimes, and L. B. Schwartz Neutralizing Endogenous IL-6 Renders Mast Cells of the MCT Type from Lung, but Not the MCTC Type from Skin and Lung, Susceptible to Human Recombinant IL-4-Induced Apoptosis J. Immunol., January 1, 2004; 172(1): 593 - 600. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. F. Zerbini, Y. Wang, J.-Y. Cho, and T. A Libermann Constitutive Activation of Nuclear Factor {kappa}B p50/p65 and Fra-1 and JunD Is Essential for Deregulated Interleukin 6 Expression in Prostate Cancer Cancer Res., May 1, 2003; 63(9): 2206 - 2215. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Alas and B. Bonavida Inhibition of Constitutive STAT3 Activity Sensitizes Resistant Non-Hodgkin's Lymphoma and Multiple Myeloma to Chemotherapeutic Drug-mediated Apoptosis Clin. Cancer Res., January 1, 2003; 9(1): 316 - 326. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Ueda, N. R. Mawji, N. Bruchovsky, and M. D. Sadar Ligand-independent Activation of the Androgen Receptor by Interleukin-6 and the Role of Steroid Receptor Coactivator-1 in Prostate Cancer Cells J. Biol. Chem., October 4, 2002; 277(41): 38087 - 38094. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Conze, L. Weiss, P. S. Regen, A. Bhushan, D. Weaver, P. Johnson, and M. Rincon Autocrine Production of Interleukin 6 Causes Multidrug Resistance in Breast Cancer Cells Cancer Res., December 1, 2001; 61(24): 8851 - 8858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-T. Lin, C.-Y. Juan, K.-J. Chang, W.-J. Chen, and M.-L. Kuo IL-6 inhibits apoptosis and retains oxidative DNA lesions in human gastric cancer AGS cells through up-regulation of anti-apoptotic gene mcl-1 Carcinogenesis, December 1, 2001; 22(12): 1947 - 1953. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Alas and B. Bonavida Rituximab Inactivates Signal Transducer and Activation of Transcription 3 (STAT3) Activity in B-Non-Hodgkin's Lymphoma through Inhibition of the Interleukin 10 Autocrine/Paracrine Loop and Results in Down-Regulation of Bcl-2 and Sensitization to Cytotoxic Drugs Cancer Res., July 1, 2001; 61(13): 5137 - 5144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Alas, C. Emmanouilides, and B. Bonavida Inhibition of Interleukin 10 by Rituximab Results in Down-Regulation of Bcl-2 and Sensitization of B-cell Non-Hodgkin's Lymphoma to Apoptosis Clin. Cancer Res., March 1, 2001; 7(3): 709 - 723. [Abstract] [Full Text]
|
|
|
|
|
|
H. J. Muenchen, D.-L. Lin, M. A. Walsh, E. T. Keller, and K. J. Pienta Tumor Necrosis Factor-{{alpha}}-induced Apoptosis in Prostate Cancer Cells through Inhibition of Nuclear Factor-{{kappa}}B by an I{{kappa}}B{{alpha}} "Super-Repressor" Clin. Cancer Res., May 1, 2000; 6(5): 1969 - 1977. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. B. Coleman, J. Momand, and S. E. Kane Basic Fibroblast Growth Factor Sensitizes NIH 3T3 Cells to Apoptosis Induced by Cisplatin Mol. Pharmacol., February 1, 2000; 57(2): 324 - 333. [Abstract] [Full Text]
|
|
|
|
|
|
J. Fan and J. R. Bertino Modulation of Cisplatinum Cytotoxicity by p53: Effect of p53-Mediated Apoptosis and DNA Repair Mol. Pharmacol., November 1, 1999; 56(5): 966 - 972. [Abstract] [Full Text]
|
|
|
|
|
|
C. A. Oskeritzian, Z. Wang, J. P. Kochan, M. Grimes, Z. Du, H.-W. Chang, S. Grant, and L. B. Schwartz Recombinant Human (rh)IL-4-Mediated Apoptosis and Recombinant Human IL-6-Mediated Protection of Recombinant Human Stem Cell Factor-Dependent Human Mast Cells Derived from Cord Blood Mononuclear Cell Progenitors J. Immunol., November 1, 1999; 163(9): 5105 - 5115. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Duan, A. J. Feller, R. T. Penson, Bruce. A. Chabner, and M. V. Seiden Discovery of Differentially Expressed Genes Associated with Paclitaxel Resistance Using cDNA Array Technology: Analysis of Interleukin (IL) 6, IL-8, and Monocyte Chemotactic Protein 1 in the Paclitaxel-resistant Phenotype Clin. Cancer Res., November 1, 1999; 5(11): 3445 - 3453. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Rancourt, A. Piche, J. Gomez-Navarro, M. Wang, R. D. Alvarez, G. P. Siegal, G. M. Fuller, S. A. Jones, and D. T. Curiel Interleukin-6 Modulated Conditionally Replicative Adenovirus as an Antitumor/Cytotoxic Agent for Cancer Therapy Clin. Cancer Res., January 1, 1999; 5(1): 43 - 50. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Ramarli, M. T. Scupoli, E. Fiorini, O. Poffe, M. Brentegani, A. Villa, G. Cecchini, G. Tridente, and P. C. Marchisio Thymocyte Contact or Monoclonal Antibody-Mediated Clustering of alpha 3beta 1 or alpha 6beta 4 Integrins Activate Interleukin-6 (IL-6) Transcription Factors (NF-kappa B and NF-IL6) and IL-6 Production in Human Thymic Epithelial Cells Blood, November 15, 1998; 92(10): 3745 - 3755. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Bihl, M. Tamm, M. Nauck, H. Wieland, A. P. Perruchoud, and M. Roth Proliferation of Human Non-Small-Cell Lung Cancer Cell Lines: Role of Interleukin-6 Am. J. Respir. Cell Mol. Biol., October 1, 1998; 19(4): 606 - 612. [Abstract] [Full Text]
|
|
|
|
|
|
R. J. Rayanade, M. I. Ndubuisi, J. D. Etlinger, and P. B. Sehgal Regulation of IL-6 Signaling by p53: STAT3- and STAT5-Masking in p53-Val135-Containing Human Hepatoma Hep3B Cell Lines J. Immunol., July 1, 1998; 161(1): 325 - 334. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
